Ten Diagnostic Approaches That Have Recently Transformed Metabolic Medicine

A State-of-the-Art Review for Postgraduate Trainees and Practicing Consultants

Dr Neeraj Manikath , claude.ai

Author: Review Article — Internal Medicine Grand Rounds Series Target Audience: Residents, Registrars, and Practicing Consultants in Internal Medicine and Endocrinology Estimated Reading Time: 25–30 minutes

Abstract

Metabolic medicine is undergoing a quiet revolution. New diagnostic paradigms — driven by continuous glucose monitoring, polygenic risk scoring, redefined cut-offs for insulin resistance, novel adipokine assays, and reclassified dyslipidemias — are forcing clinicians to rethink conditions they thought they understood. This review synthesises ten diagnostic shifts that have materially changed how expert clinicians approach metabolic disorders. Framed for bedside application rather than bench science, each section offers clinical pearls, hidden oysters, and practical hacks drawn from current best evidence. Postgraduate trainees who absorb these principles will separate themselves from their peers at the ward, in the clinic, and at the examination table.

Opening Vignette: The Case That Changes How You Think

A 44-year-old software engineer presents for a routine health check. His fasting glucose is 5.8 mmol/L (104.4 mg/dL), HbA1c is 5.6%, and his BMI is 26.4 kg/m². His lipid panel shows LDL 2.9 mmol/L and HDL 1.1 mmol/L. You reassure him he is "metabolically normal." Three years later, he returns with a STEMI.

Was he ever normal? Almost certainly not. His fasting triglycerides were 2.8 mmol/L. His waist circumference was 98 cm. His HOMA-IR, never checked, would have been 3.6. His non-alcoholic fatty liver disease (NAFLD) fibrosis score, never calculated, would have flagged significant steatosis. Every one of these data points was available at the first visit. The diagnostic tools existed. The paradigm to use them did not.

This case is not unusual. It is instructive. What follows are ten diagnostic shifts that, had they been applied in that consultation room, might have told a different story.

1. The Redefinition of Prediabetes: Two-Hour OGTT Is Non-Negotiable

For over a decade, prediabetes has been diagnosed using fasting glucose (5.6–6.9 mmol/L) or HbA1c (5.7–6.4%). These criteria, while pragmatic, are epidemiologically incomplete.

The landmark ADDITION-Cambridge cohort and subsequent analyses from the EPIC-Norfolk study confirmed that isolated post-load hyperglycaemia (IPH) — defined as a normal fasting glucose but 2-hour OGTT glucose ≥ 7.8 mmol/L — carries a cardiovascular risk equivalent to frank type 2 diabetes, yet is missed by fasting-only screening in up to 30–40% of at-risk individuals.¹

🪙 Clinical Pearl: A normal fasting glucose does NOT exclude significant glucose dysregulation. In lean South Asian patients — where metabolic dysfunction occurs at lower BMI — the HbA1c-to-glucose correlation is particularly unreliable. Always perform a 75g OGTT in high-risk individuals with a "normal" fasting glucose.

🦪 Oyster: The 1-hour glucose during an OGTT (≥ 8.6 mmol/L) has emerged as a superior predictor of incident diabetes and cardiovascular events compared to the 2-hour value, per data from the STOP-NIDDM and Relationship Between Insulin Sensitivity and Cardiovascular Disease (RISC) cohorts. Most labs do not routinely measure the 1-hour sample. Request it explicitly.

⚡ Clinical Hack: In resource-limited settings, a 1-hour post-breakfast capillary glucose (taken 60 minutes after a standardised meal) > 8.5 mmol/L correlates strongly with 2-hour OGTT ≥ 7.8 mmol/L and can serve as a practical triage tool.

2. HOMA-IR: The Forgotten Metabolic Fingerprint

Insulin resistance is the metabolic substrate of type 2 diabetes, metabolic syndrome, PCOS, NAFLD, hypertension, and arguably certain cancers — yet most clinicians never measure it directly.

HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) = Fasting glucose (mmol/L) × Fasting insulin (µIU/mL) ÷ 22.5

A HOMA-IR ≥ 2.5 defines insulin resistance in most Western cohorts; ≥ 2.0 in South Asian and East Asian populations given their lower threshold for metabolic harm.²

🪙 Clinical Pearl: A patient with a HOMA-IR of 4.5 and a "normal" HbA1c of 5.4% is metabolically ill. Their beta cells are compensating magnificently — for now. What you are seeing is a burning building with no smoke alarm yet. The absence of hyperglycaemia is not the absence of disease.

🦪 Oyster: The Triglyceride-Glucose (TyG) Index — calculated as ln(fasting triglycerides [mg/dL] × fasting glucose [mg/dL] ÷ 2) — is a free, validated surrogate for HOMA-IR that requires no insulin assay. A TyG index ≥ 8.5 identifies insulin resistance with sensitivity > 85% and is increasingly used in low-resource settings.³ Most clinicians have never heard of it.

⚡ Clinical Hack: To quickly assess insulin resistance at the bedside without any investigations: waist circumference > 90 cm (Asian) or > 102 cm (Caucasian male) + fasting TG ≥ 1.7 mmol/L + HDL < 1.0 mmol/L = almost certainly insulin resistant. No blood test needed to start the conversation.

3. The End of the "Normal BMI Is Safe" Paradigm: Metabolically Obese Normal Weight (MONW)

The concept of Metabolically Obese, Normal Weight (MONW) — individuals with BMI < 25 but with visceral adiposity, insulin resistance, and cardiometabolic risk — has moved from academic curiosity to clinical imperative.

Using DEXA-defined body fat percentage and visceral fat area (via CT), studies from the Korean NHANES and MESA cohorts demonstrate that nearly 25% of individuals with a "normal" BMI harbour significant visceral adiposity with metabolic syndrome components.⁴

Conversely, Metabolically Healthy Obesity (MHO) — obese individuals without insulin resistance or cardiometabolic risk factors — carries substantially lower cardiovascular risk, though this is a dynamic state.

🪙 Clinical Pearl: Stop reassuring patients with normal BMI that they are "fine." In South Asian populations, metabolic risk begins at BMI ≥ 23 kg/m². The IDF and WHO Asia-Pacific guidelines have endorsed separate cut-offs since 2004, yet they remain underused in clinical practice.

🦪 Oyster: The waist-to-height ratio (WHtR) — simply waist circumference divided by height in the same units — is more predictive of cardiometabolic risk than BMI or waist circumference alone. A WHtR ≥ 0.5 is the threshold. It requires a tape measure and no calculator. It has been called "the single best anthropometric predictor of metabolic risk" in multiple meta-analyses.⁵ Use it in every metabolic consultation.

⚡ Clinical Hack: "Keep your waist to less than half your height" is a message patients remember. It is doctor-independent, culturally transferable, and evidence-based. Use it.

4. Reclassification of Dyslipidaemia: Beyond LDL Cholesterol

The LDL-centric paradigm of dyslipidaemia management, while foundational, is no longer sufficient. Three diagnostic shifts deserve specific attention:

4a. Non-HDL Cholesterol as the Primary Target

Non-HDL cholesterol (= Total cholesterol − HDL) captures all atherogenic lipoproteins — LDL, VLDL, IDL, Lp(a), and remnant particles. The ESC/EAS 2019 and AHA/ACC 2022 guidelines now explicitly endorse non-HDL-C as a co-primary target alongside LDL-C, especially in patients with hypertriglyceridaemia, diabetes, and metabolic syndrome.⁶

4b. Lipoprotein(a): The Underdiagnosed Risk Amplifier

Lp(a) is genetically determined, not modifiable by lifestyle, and causes premature atherosclerosis, aortic valve disease, and recurrent cardiovascular events. It should be measured at least once in every adult's lifetime. An Lp(a) > 50 mg/dL (>125 nmol/L) reclassifies cardiovascular risk and warrants intensification of LDL-lowering therapy as a bridge until Lp(a)-specific therapies (pelacarsen, olpasiran) enter mainstream practice.

4c. Remnant Cholesterol: The Missing Piece

Remnant cholesterol — calculated as Total cholesterol − LDL − HDL — reflects VLDL and IDL particles increasingly recognised as directly atherogenic. A remnant cholesterol > 0.8 mmol/L is associated with increased cardiovascular risk independent of LDL.⁷

🪙 Clinical Pearl: A patient with LDL-C of 1.8 mmol/L post-statin but TG of 4.0 mmol/L, HDL of 0.8 mmol/L, and high remnant cholesterol is far from "lipid controlled." Residual risk is not residual complication — it is ongoing pathology.

🦪 Oyster: Request apolipoprotein B (ApoB) rather than LDL-C in patients with metabolic syndrome or diabetes. ApoB measures the total number of atherogenic particles directly, avoids the Friedewald calculation error in hypertriglyceridaemia, and is the most accurate predictor of cardiovascular events in insulin-resistant patients. Target: ApoB < 65 mg/dL in very high-risk patients.

5. NAFLD to MASLD: A Diagnostic Reclassification That Changes Risk Stratification

In 2023, an international multisociety consensus renamed Non-Alcoholic Fatty Liver Disease (NAFLD) to Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD). This is not merely semantic — it has diagnostic implications.

MASLD now requires the presence of hepatic steatosis plus at least one cardiometabolic risk factor (raised BMI, dysglycaemia, hypertension, dyslipidaemia). This framework:

Removes the need to exclude alcohol entirely (a new category, MetALD, covers modest alcohol use)
Explicitly ties the diagnosis to metabolic dysfunction
Enables coexistence with other liver conditions

🪙 Clinical Pearl: The FIB-4 score (Age × AST ÷ [Platelet count × √ALT]) is the validated first-line non-invasive fibrosis assessment tool recommended by EASL/AASLD 2023. A score < 1.30 effectively excludes significant fibrosis (F2+) with high NPV. A score ≥ 2.67 warrants hepatology referral. The intermediate zone (1.30–2.67) requires LSM (liver stiffness measurement) by FibroScan.⁸

🦪 Oyster: Normal transaminases do NOT exclude significant MASLD. Up to 79% of patients with biopsy-proven NASH (now MASH) have normal ALT. Never use a normal AST/ALT to reassure a metabolically high-risk patient that their liver is healthy.

⚡ Clinical Hack: Calculate the FIB-4 score on every diabetic patient you see. It takes 30 seconds and a basic metabolic panel. It will identify a proportion with advanced fibrosis who require immediate hepatology referral and who are at risk of hepatocellular carcinoma — a diagnosis most internists would otherwise miss until it is far too late.

6. Continuous Glucose Monitoring in Non-Diabetics: A Diagnostic Paradigm Shift

Continuous Glucose Monitoring (CGM) is no longer confined to insulin-dependent diabetics. Its application in metabolic diagnostics represents one of the most significant paradigm shifts in endocrinology in the last decade.

CGM-derived metrics — particularly Time in Range (TIR), Time Above Range (TAR), Glucose Management Indicator (GMI), and Coefficient of Variation (CV) — provide mechanistic insight no static glucose or HbA1c can match.

Studies have demonstrated significant postprandial hyperglycaemic excursions in individuals with normal fasting glucose and normal HbA1c — excursions that predict subclinical atherosclerosis, endothelial dysfunction, and incident diabetes.⁹

🪙 Clinical Pearl: HbA1c represents a 90-day weighted average but is blind to glycaemic variability. Two patients can have identical HbA1c yet profoundly different glucose profiles — one flatlined, one swinging violently. High CV (> 36%) independently predicts hypoglycaemic episodes and cardiovascular events. This is invisible to HbA1c.

🦪 Oyster: In patients with unexplained fatigue, cognitive fog, palpitations, or anxiety — especially in the late postprandial period (2–4 hours after meals) — a blinded 14-day CGM can diagnose reactive hypoglycaemia and late dumping physiology that would never be captured by any fasting investigation. This remains dramatically underdiagnosed.

⚡ Clinical Hack: A 14-day blinded CGM study (now available on prescription in many countries) gives more metabolic information than six months of HbA1c monitoring. In complex prediabetic patients, high-risk post-bariatric surgery patients, or those with steroid-induced dysglycaemia, it is transformative.

7. Thyroid Function Testing: Subclinical Disease Redefined

The debate around subclinical hypothyroidism (SCH) — TSH elevated but FT4 normal — has been fundamentally reframed by three developments:

Age-stratified TSH reference ranges: TSH rises physiologically with age. A TSH of 5.2 mIU/L in a 75-year-old is not the same clinical entity as in a 35-year-old. Studies using longitudinal data suggest treating SCH in the elderly may confer no benefit and possible harm (TRUST trial, 2017).¹⁰
Anti-TPO antibody status: SCH with anti-TPO antibodies positive carries a 4–5× higher rate of progression to overt hypothyroidism. This dramatically changes the decision to treat.
TSH-FT3 discordance in levothyroxine-treated patients: Up to 15% of levothyroxine-treated patients have persistently low FT3 despite normal TSH, due to impaired T4-to-T3 conversion. These patients report ongoing symptoms and may benefit from combination T4/T3 therapy — a nuance most prescribers miss.

🪙 Clinical Pearl: Do not interpret TSH in isolation. Always check anti-TPO antibodies in any patient with TSH 2.5–10 mIU/L, and assess FT3 (not just FT4) in symptomatic levothyroxine-treated patients with a "normal" TSH.

🦪 Oyster: Central hypothyroidism — pituitary-dependent — presents with a low/normal TSH and low FT4. A clinician reflexively reassured by a "normal" TSH will catastrophically miss this diagnosis. Always check FT4 in patients with suspected pituitary disease, prior head irradiation, or unexplained metabolic depression despite normal TSH.

8. Adrenal Incidentaloma and Mild Autonomous Cortisol Secretion (MACS): The Hidden Metabolic Disruptor

The widespread use of cross-sectional imaging has created a new diagnostic entity: the adrenal incidentaloma. Prevalence at autopsy exceeds 6%. Approximately 30–40% of incidentally discovered adrenal adenomas demonstrate Mild Autonomous Cortisol Secretion (MACS) — formerly called "subclinical Cushing's syndrome."¹¹

MACS is diagnosed when the post-1mg overnight dexamethasone suppression test (DST) shows cortisol > 50 nmol/L (1.8 µg/dL) in the absence of classical Cushingoid features. Yet these patients harbour significantly elevated rates of:

Type 2 diabetes and insulin resistance
Hypertension
Dyslipidaemia
Vertebral fractures
Cardiovascular events

🪙 Clinical Pearl: The Endocrine Society 2023 guidelines now recommend that all adrenal incidentalomas ≥ 1 cm undergo a 1mg DST, regardless of imaging characteristics. MACS is clinically silent by definition — you will not find it if you do not look.

🦪 Oyster: In any patient with difficult-to-control hypertension, insulin resistance, and osteoporosis — even without classical Cushingoid features — consider MACS. The triad of metabolic syndrome + adrenal incidentaloma should prompt immediate cortisol assessment. This is one of the most commonly missed reversible causes of metabolic syndrome.

⚡ Clinical Hack: Order the 1mg overnight DST as an outpatient investigation. Dexamethasone 1mg at 11 pm; fasting cortisol at 8–9 am the next morning. If cortisol > 50 nmol/L, escalate with 24-hour UFC and late-night salivary cortisol. The investigation costs almost nothing and changes management profoundly.

9. Primary Hyperaldosteronism: Vastly Underdiagnosed, Dramatically Undertested

Primary hyperaldosteronism (PA) — autonomous aldosterone secretion from adrenal adenoma or bilateral adrenal hyperplasia — is now recognised as the most common cause of secondary hypertension, present in 5–10% of all hypertensive patients and potentially 20–30% of those with treatment-resistant hypertension.¹² Yet testing rates in most practices remain dismally low.

The screening test — Aldosterone-to-Renin Ratio (ARR) — is a simple blood draw, yet it is ordered in fewer than 2% of eligible hypertensive patients in most audits.

Who to screen (updated 2023 Endocrine Society guidance):

Hypertension with spontaneous or diuretic-induced hypokalaemia
Resistant hypertension (BP uncontrolled on ≥ 3 agents including a diuretic)
Hypertension with adrenal incidentaloma
Hypertension with obstructive sleep apnoea
Hypertension with a first-degree relative with PA
Onset of hypertension < 40 years

🪙 Clinical Pearl: PA is NOT a diagnosis of hypokalaemia. Over 70% of patients with confirmed PA have normal serum potassium. Using hypokalaemia as the screening criterion is equivalent to screening for diabetes only in symptomatic patients — you miss most of the disease.

🦪 Oyster: Aldosterone has direct, potassium-independent metabolic effects: it promotes insulin resistance, inflammation, and myocardial fibrosis. PA patients have significantly higher rates of atrial fibrillation, left ventricular hypertrophy, metabolic syndrome, and cardiovascular events than BMI-matched essential hypertensives at the same blood pressure. The metabolic harm of PA exceeds the haemodynamic harm.

⚡ Clinical Hack: Spironolactone as an empirical fourth-line antihypertensive in a resistant hypertensive is both therapeutic and diagnostic. A dramatic BP response to a mineralocorticoid receptor antagonist should immediately raise suspicion for PA and prompt formal ARR testing.

10. Polygenic Risk Scores and the Era of Precision Metabolic Risk Prediction

The final frontier — and the one that will define the next decade of metabolic medicine — is Polygenic Risk Scoring (PRS) for metabolic disease.

PRS aggregates the effect of thousands of common genetic variants, each with small individual effect, into a single composite risk estimate. PRS for type 2 diabetes, coronary artery disease, and obesity have now been validated in large prospective cohorts including UK Biobank (n > 500,000).¹³

Crucially, high PRS identifies individuals at elevated lifetime risk decades before clinical disease, enabling targeted preventive intervention when it is still possible to alter the trajectory.

🪙 Clinical Pearl: A patient in the top 8% of the T2DM PRS distribution has a lifetime risk equivalent to a monogenic mutation carrier. PRS is not a niche academic tool — it is a clinically actionable stratification instrument that will enter mainstream primary prevention within this decade.

🦪 Oyster: PRS also identifies the "resilient" phenotype — individuals with high genetic risk who remain metabolically healthy. Studying these individuals has yielded insights into novel protective mechanisms (e.g., AMPK pathway activation, superior mitochondrial biogenesis) that are now therapeutic targets. Understanding why some high-risk individuals escape disease is as clinically important as understanding why others succumb to it.

⚡ Clinical Hack: Even without formal PRS, a thorough three-generation family history — first-degree relatives with T2DM, premature CAD, stroke, or NAFLD — provides a practical clinical proxy for genetic risk. Systematic family history documentation remains underperformed in almost every outpatient practice.

Summary Table: 10 Diagnostic Shifts at a Glance

#	Diagnostic Shift	Old Approach	New Standard	Action Point
1	Prediabetes Diagnosis	Fasting glucose + HbA1c	Add 75g OGTT; check 1h glucose	Order OGTT in all high-risk patients
2	Insulin Resistance	Rarely measured	HOMA-IR / TyG Index	Integrate into metabolic risk assessment
3	BMI & Adiposity	BMI-centric	WHtR > 0.5; MONW concept	Measure waist and height in every patient
4	Dyslipidaemia	LDL-C only	Non-HDL-C, ApoB, Lp(a), remnant	Measure Lp(a) once; use ApoB in insulin resistance
5	Fatty Liver	NAFLD by exclusion	MASLD; FIB-4 routine in diabetes	Calculate FIB-4 in every diabetic patient
6	Glycaemic Monitoring	HbA1c	CGM, TIR, GMI, CV	Consider 14-day CGM in complex cases
7	Thyroid Function	TSH alone	Age-stratified; FT3; anti-TPO	Check FT3 in symptomatic levothyroxine patients
8	Adrenal Adenoma	Imaging only	Mandatory 1mg DST; screen for MACS	DST for all adrenal incidentalomas ≥ 1 cm
9	Secondary Hypertension	Test only if hypokalaemic	ARR in all resistant/young hypertensives	Normalise ARR testing in hypertension clinics
10	Genetic Risk	Ignored in practice	Polygenic risk scoring; family history	Document three-generation metabolic family history

A Mnemonic for the Wards: "PRIME-WATCH"

P — Postprandial glucose (OGTT; 1-hour sample) R — Remnant cholesterol / Renin-aldosterone ratio I — Insulin resistance (HOMA-IR / TyG Index) M — MASLD / FIB-4 (in every diabetic) E — Endocrine causes of metabolic syndrome (MACS, PA)

W — Waist-to-height ratio (≥ 0.5 is abnormal) A — ApoB / Lp(a) (beyond LDL-C) T — Thyroid FT3 in symptomatic patients on levothyroxine C — CGM (for glycaemic variability, not just HbA1c) H — Hereditary/Polygenic risk (family history documentation)

When to Escalate vs. When to Watch

Clinical Scenario	Watch	Escalate
OGTT 2h glucose 7.8–10.9 mmol/L	Lifestyle, repeat at 6 months	If HOMA-IR > 3 or TyG high → Metformin / GLP-1 RA
FIB-4 1.30–2.67 (indeterminate)	Repeat in 12 months	LSM (FibroScan) → hepatology if ≥ 8 kPa
1mg DST cortisol 50–138 nmol/L	Annual repeat, metabolic monitoring	If > 138 nmol/L or metabolic sequelae → endocrinology
ARR elevated (> 30 ng/dL per ng/mL/h)	Confirm with repeat	Confirmatory test (saline infusion) → adrenal CT → adrenal vein sampling
MONW with WHtR > 0.5, TyG > 8.5	Lifestyle intervention, 3-monthly monitoring	If HbA1c rising, BP uncontrolled or MACS suspected → specialist referral

Conclusions: The Metabolism You Were Never Taught to See

The metabolic patient sitting in front of you may have normal glucose, normal BMI, normal LDL, and normal thyroid function — and yet be on a fast track to their first cardiovascular event or hepatic decompensation.

The ten diagnostic shifts reviewed here share a common thread: they require clinicians to look beyond the obvious, challenge comfortable cut-offs, and use the tools already available in a more sophisticated way. None of them require expensive or experimental investigations. All of them are available to the practising internist today.

The internist of the next decade will be defined not by what investigations they order, but by knowing which patient needs which investigation, why, and what to do with the result. The paradigms described here are that map.

"The first duty of medicine is to make the diagnosis. The second is to make sure the diagnosis is complete." — Sir William Osler (paraphrased for metabolic medicine, 2025)

References

Færch K, Johansen NB, Witte DR, et al. Relationship between insulin resistance and β-cell dysfunction in subphenotypes of prediabetes and type 2 diabetes. J Clin Endocrinol Metab. 2015;100(2):707–716.
Gayoso-Diz P, Otero-González A, Rodriguez-Alvarez MX, et al. Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population. Eur J Endocrinol. 2013;168(1):101–109.
Guerrero-Romero F, Simental-Mendía LE, González-Ortiz M, et al. The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemic-hyperinsulinemic clamp. J Clin Endocrinol Metab. 2010;95(7):3347–3351.
Wildman RP, Muntner P, Reynolds K, et al. The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering. Arch Intern Med. 2008;168(15):1617–1624.
Ashwell M, Gunn P, Gibson S. Waist-to-height ratio is a better screening tool than waist circumference and BMI for adult cardiometabolic risk factors. Obes Rev. 2012;13(3):275–286.
Mach F, Baigent C, Catapano AL, et al; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2020;41(1):111–188.
Varbo A, Benn M, Tybjærg-Hansen A, et al. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol. 2013;61(4):427–436.
Rinella ME, Lazarus JV, Ratziu V, et al; NAFLD Nomenclature Consensus Group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966–1986.
Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006;295(14):1681–1687.
Stott DJ, Rodondi N, Kearney PM, et al; TRUST Study Group. Thyroid hormone therapy for older adults with subclinical hypothyroidism. N Engl J Med. 2017;376(26):2534–2544.
Fassnacht M, Arlt W, Bancos I, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline. Eur J Endocrinol. 2023;188(1):G1–G42.
Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(5):1889–1916.
Khera AV, Chaffin M, Aragam KG, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nat Genet. 2018;50(9):1219–1224.
Lim EL, Hollingsworth KG, Aribisala BS, et al. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia. 2011;54(10):2506–2514.
Nikolopoulou A, Kadoglou NP. Obesity and metabolic syndrome as related to cardiovascular disease. Expert Rev Cardiovasc Ther. 2012;10(7):933–939.

Conflict of interest: None declared. Funding: None. This article represents the personal opinions and clinical synthesis of the author and does not constitute formal clinical guideline endorsement.

learningmedicine

Friday, May 29, 2026